Lorcaserin HClCAS# 846589-98-8 |
- Mosapride
Catalog No.:BCC4078
CAS No.:112885-41-3
- Pizotifen
Catalog No.:BCC4215
CAS No.:15574-96-6
- Pizotifen Malate
Catalog No.:BCC4825
CAS No.:5189-11-7
- Fluvoxamine
Catalog No.:BCC4214
CAS No.:54739-18-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 846589-98-8 | SDF | Download SDF |
| PubChem ID | 11673085 | Appearance | Powder |
| Formula | C11H15Cl2N | M.Wt | 232.15 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | (5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;hydrochloride | ||
| SMILES | CC1CNCCC2=C1C=C(C=C2)Cl.Cl | ||
| Standard InChIKey | ITIHHRMYZPNGRC-QRPNPIFTSA-N | ||
| Standard InChI | InChI=1S/C11H14ClN.ClH/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9;/h2-3,6,8,13H,4-5,7H2,1H3;1H/t8-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Lorcaserin HCl Dilution Calculator
Lorcaserin HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.3076 mL | 21.5378 mL | 43.0756 mL | 86.1512 mL | 107.689 mL |
| 5 mM | 0.8615 mL | 4.3076 mL | 8.6151 mL | 17.2302 mL | 21.5378 mL |
| 10 mM | 0.4308 mL | 2.1538 mL | 4.3076 mL | 8.6151 mL | 10.7689 mL |
| 50 mM | 0.0862 mL | 0.4308 mL | 0.8615 mL | 1.723 mL | 2.1538 mL |
| 100 mM | 0.0431 mL | 0.2154 mL | 0.4308 mL | 0.8615 mL | 1.0769 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
selective full agonist of human 5-HT2C receptor with Ki of 15 nM.
- Decinnamoyltaxinine J
Catalog No.:BCN7210
CAS No.:84652-33-5
- Tea polyphenol
Catalog No.:BCN8518
CAS No.:84650-60-2
- 4-Nitrobenzyl dimethylcarbamate
Catalog No.:BCN3284
CAS No.:84640-31-3
- Eurycomanone
Catalog No.:BCN2990
CAS No.:84633-29-4
- Itraconazole
Catalog No.:BCC4914
CAS No.:84625-61-6
- H-Lys(Fmoc)-OH
Catalog No.:BCC2984
CAS No.:84624-28-2
- Boc-Lys(Fmoc)-OH
Catalog No.:BCC3417
CAS No.:84624-27-1
- Fmoc-D-Val-OH
Catalog No.:BCC3573
CAS No.:84624-17-9
- Cyclogalegigenin
Catalog No.:BCN6295
CAS No.:84605-18-5
- Lorazepam
Catalog No.:BCC5970
CAS No.:846-49-1
- Boldenone
Catalog No.:BCC8892
CAS No.:846-48-0
- 5α-Androstanedione
Catalog No.:BCC8752
CAS No.:846-46-8
- Isoastragaloside I
Catalog No.:BCN2979
CAS No.:84676-88-0
- Astragaloside II
Catalog No.:BCN5962
CAS No.:84676-89-1
- Enalaprilat Dihydrate
Catalog No.:BCC5009
CAS No.:84680-54-6
- 3-O-(2'E,4'Z-Decadienoyl)ingenol
Catalog No.:BCN3767
CAS No.:84680-59-1
- Astragaloside I
Catalog No.:BCN5961
CAS No.:84680-75-1
- Astragaloside III
Catalog No.:BCN5963
CAS No.:84687-42-3
- Astragaloside IV
Catalog No.:BCN5960
CAS No.:84687-43-4
- Arglabin
Catalog No.:BCC5299
CAS No.:84692-91-1
- UVI 3003
Catalog No.:BCC7638
CAS No.:847239-17-2
- Calceolarioside A
Catalog No.:BCN5347
CAS No.:84744-28-5
- Qingyangshengenin
Catalog No.:BCN4389
CAS No.:84745-94-8
- Eriocalyxin B
Catalog No.:BCN4390
CAS No.:84745-95-9
Lorcaserin Hcl for the treatment of obesity.[Pubmed:26472579]
Expert Opin Pharmacother. 2015;16(16):2531-8.
INTRODUCTION: Obesity is a major health priority necessitating safe and effective strategies to address the obesity epidemic. Lorcaserin is a serotonergic agonist specific to the 5HT- 2C receptor approved for chronic management of obesity in patients with a BMI >/= 30 kg/m(2) or a BMI >/= 27 kg/m(2) with comorbidities related to obesity. AREAS COVERED: In this paper, the pharmacodynamic and pharmacokinetic properties of lorcaserin are reviewed followed by a discussion of efficacy and safety data from major clinical trials. EXPERT OPINION: Lorcaserin is a unique highly selective serotonergic agonist designed to mitigate the risks associated with previous agents in this class. At therapeutic doses, it is well tolerated and produces modest but clinically meaningful weight loss with significant improvement in cardiometabolic parameters. Therapeutic efficacy should be assessed at 12 weeks (>/= 5% weight loss) to identify responders who will derive maximum weight loss and metabolic benefit from long-term therapy. The results of the ongoing cardiovascular outcomes trial (CAMELLIA TIMI 61) will determine the role of lorcaserin in primary prevention of diabetes in overweight/obese individuals and its use in the high-risk population of patients with established cardiovascular disease or multiple cardiovascular risk factors.
